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Abstract
In a number of human cancers, NTN1 upregulation inhibits apop-
tosis induced by its so-called dependence receptors DCC and
UNC5H, thus promoting tumor progression. In other cancers
however, the selective inhibition of this dependence receptor
death pathway relies on the silencing of pro-apoptotic effector
proteins. We show here that a substantial fraction of human
breast tumors exhibits simultaneous DNA methylation-dependent
loss of expression of NTN1 and of DAPK1, a serine threonine kinase
known to transduce the netrin-1 dependence receptor pro-apop-
totic pathway. The inhibition of DNA methylation by drugs such as
decitabine restores the expression of both NTN1 and DAPK1 in
netrin-1-low cancer cells. Furthermore, a combination of decita-
bine with NTN1 silencing strategies or with an anti-netrin-1
neutralizing antibody potentiates tumor cell death and efficiently
blocks tumor growth in different animal models. Thus, combining
DNA methylation inhibitors with netrin-1 neutralizing agents may
be a valuable strategy for combating cancer.
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Introduction
Recent research focusing on a specific functional family of receptors,
namely the dependence receptors (DRs) (Mehlen et al, 1998; Llambi
et al, 2001), has highlighted their implication in inhibiting tumor
progression. Indeed, in contrast to most cellular receptors, a dual
role characterizes these transmembrane receptors: in the presence
of their respective ligands, they provide a typical positive signal
(promoting cell survival, migration, proliferation, etc.), while the
absence of ligand triggers a cascade of signaling events leading to
apoptotic cell death. The DR protein family currently contains
approximately twenty known members, and one of their most
exhaustively studied ligands is Netrin-1. This DR ligand was the first
secreted attractive axon guidance cue to be described in the early
nineties, since then, the role of netrin-1 in many biological functions
has been established (Cirulli & Yebra, 2007; Mehlen & Guenebeaud,
2010; Ramkhelawon et al, 2014). Netrin-1 receptors, namely, are
the Deleted in Colorectal Carcinoma (DCC), the Uncoordinated-5-
Homologs (UNC5H1-4/A–D). The ability of these receptors to trigger
apoptosis in settings under ligand-limited conditions was shown to
be a constrain for impede tumor progression. Indeed, the inactiva-
tion of UNC5C, and DCC, or the mutation of the DCC-inducing apop-
tosis domain is associated with tumor development and progression
in mouse models (Bernet et al, 2007; Castets et al, 2012; Krimpenfort
et al, 2012). Furthermore, in line with these observations, DCC and
UNC5H are silenced in many cancers, either by loss of heterozygos-
ity or epigenetic mechanisms (Hedrick et al, 1994; Bernet et al,
2007; Shin et al, 2007). Alternatively, in some types of cancers, an
upregulation of NTN1 provides a similar tumor growth selective
advantage by abolishing their dependency on netrin-1 availability in
the micro-environment (Fitamant et al, 2008). This upregulation is
particularly marked in some cases of aggressive breast cancer and
in breast metastasis (Fitamant et al, 2008; Harter et al, 2014). The
reliance on netrin-1 for tumor growth was rapidly perceived as an
opportunity for therapeutic intervention, since it was speculated that
the disruption of the binding of netrin-1 to its receptors should
induce apoptotic cell death in vitro and tumor growth inhibition
in vivo. Consistently, the silencing of netrin-1 or the development of
biological agents interfering with netrin-1/DRs interactions has been
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shown to efficiently reduce tumor growth and metastasis in different
animal models (Fitamant et al, 2008; Delloye-Bourgeois et al,
2009a,b; Paradisi et al, 2013; Grandin et al, 2016). Moreover, an
anti-netrin-1 antibody is under preclinical evaluation and should be
assessed in early clinical trials in 2016.
Nevertheless, a substantial fraction of human tumors appears to
conserve the expression of netrin-1 receptors without upregulating
NTN1 expression, suggesting that the downstream DR pathways
may be impaired (Shin et al, 2007; Mian et al, 2011; Krimpenfort
et al, 2012). In cancers, epigenetic modifications are frequently
associated with an increase in the expression of anti-apoptotic
proteins and with the inactivation of factors inducing apoptosis
(Baylin & Ohm, 2006). In this context, previous studies have
reported that DAPK1, a serine threonine kinase responsible for
UNC5H-induced apoptosis, is downregulated in various cancers
(Llambi et al, 2005; Guenebeaud et al, 2010). Furthermore, mecha-
nistic analyses have demonstrated a direct relationship between the
hypermethylation of the CpG island (CGi) located within the DAPK1
promoter region and its downregulation (Raval et al, 2007; Pulling
et al, 2009; Mian et al, 2011; Kilinc et al, 2012). Finally, it was
shown that treatment with decitabine (5-aza-20-deoxycytidine, DAC)
inhibits the DNA methylation of the DAPK1 promoter and restores
DAPK1 expression in lung cancer cell lines (Tang et al, 2004).
Inhibition of DNA methylation may prove to be a promising
approach for combating cancer (Yang et al, 2010; Rodriguez-
Paredes & Esteller, 2011a; Dawson & Kouzarides, 2012; Tsai et al,
2012). Concordantly, DAC showed anti-leukemic effects in several
clinical trials and has been approved by FDA for the treatment of
myelodysplastic syndromes and recent studies indicated that DAC
shows some effects in preclinical models (Tsai et al, 2012). Here,
we report that treatment with DAC restores the pro-apoptotic
machinery linked to the netrin-1/DR-mediated cell death signaling
pathway in breast cancer cell lines and patient-derived xenografts
and sensitize cancer cells to netrin-1 neutralizing agents. We thus
provide evidence that combining DNA methylation inhibitors with a
netrin-1 neutralizing antibody empowers tumor cell death in vitro
and tumor growth inhibition in mice.
Results
Epigenetic downregulation of netrin-1 is associated with the
epigenetic downregulation of DAPK1, in human breast cancers
In order to study the mechanisms underlying inhibition of netrin-1/
DRs-mediated apoptosis, which in a fraction of tumors is neither
dependent on netrin-1 upregulation nor DR silencing, we investi-
gated DAPK1 expression and DNA methylation in breast tumors.
We thus examined differentially methylated regions (DMRs)
associated with malignant transformation in breast cancer samples
(n = 92) available from The Cancer Genome Atlas (TCGA) by
comparing paired normal/tumoral data obtained from the
HumanMethylation450K Array (HM450, Illumina) and by high-
throughput sequencing of polyadenylated RNA (RNAseq). This
comparison focused on the level of DNA methylation within the
50-end of NTN1 (position 765 to + 1,300 relative to the transcription
start site, TSS) and DAPK1 (+ 365 and + 838 relative to the TSS) and
revealed that these regions were hypermethylated (threshold = 2) in
about 30% of tumoral samples compared with their normal counter-
parts (Fig 1A and B). Furthermore, NTN1 was downregulated
(Fig 1C, fold change (FC) ≤ 0.5) in 43% of cases and the “NTN1-
low” samples were hypermethylated (Fig 1G; P = 3 × 102, two-
sided Mann–Whitney test) when compared with samples exhibiting
no NTN1 downregulation (FC ≥ 1.3). Using the same approach for
DAPK1, we observed that samples exhibiting DAPK1 downregula-
tion (29% of the samples, Fig 1D) were also hypermethylated
(P = 3 × 104) when compared with the other samples (Fig 1H).
These epigenetic modifications did not seem to be independent
events since in NTN1-hypermethylated samples (n = 23, FC ≥ 2),
DAPK1 was also hypermethylated (mean FC = 2.22), while in
NTN1-hypomethylated samples (n = 13, FC < 0.7), DAPK1 was not
hypermethylated (mean FC = 0.93). The relationship between
DAPK1/NTN1 downregulation and DNA hypermethylation was also
observed in a larger number of breast cancer samples (n = 807)
available on TCGA data portal. Indeed, the mean percentage of CpG
methylation (Fig 1E and F) of DAPK1 and NTN1 were inversely
correlated with their levels of expression (Pearson’s r = 0.32,
P < 1018 and Pearson’s r = 0.14, P = 6.7 × 105, respectively),
suggesting that DNA methylation represses DAPK1 and NTN1 tran-
scription in human breast tumors.
Although we cannot excluded a bias due to stromal contamina-
tion, it should be noted that, in paired samples, while hypermethyla-
tion was observed in tumoral tissues, very low levels of DNA
methylation were measured in their normal counterparts (Fig 1A
and B). For both genes, a region (not represented on HM450)
located at the 30-end of the CGis (Fig 2A, light gray boxes) was
selected for the quantitative analysis of DNA methylation of breast
cancer biopsies (tumor bank—Centre Le´on Be´rard) by bisulfite
pyrosequencing. The analysis indicated that the mean percentage of
CpG methylation of the DAPK1 and NTN1 pyrosequenced regions
were inversely correlated (Pearson’s r = 0.66, P = 0.003, and Pear-
son’s r = 0.55, P = 0.008, respectively) with their levels of expres-
sion (Fig EV1A and B). Altogether, these data suggested that DNA
methylation is involved in the downregulation of NTN1 and DAPK1
in human breast cancers.
To determine whether this concomitant change in DAPK1 and
NTN1 expression was also observed at the protein levels, DAPK1,
UNC5B, and netrin-1 were measured by immunohistochemistry
(IHC) using tissue microarrays (70 sections) from human breast
ductal carcinoma (Super Bio Chips). This analysis revealed, that,
netrin-1-low samples also exhibited low levels of DAPK1 (v2 test,
P = 0.04). In contrast, UNC5B levels were the same, irrespective of
netrin-1 levels (Fig EV1C and D). This result was validated in the
TCGA cohort of breast tumors samples (n = 807), where a correla-
tion between DAPK1 and NTN1 expression was observed (odd
ratio = 4.71, P = 0.03, Fig EV1E).
In order to establish an in vitro experimental model mimicking
the DNA methylation alterations observed in breast cancer tissues,
DNA methylation patterns of two cancer cell lines were determined
by parallel sequencing. Pull-down assays were conducted using the
MDA-MB-231 cell line derived from human breast cancer, and the
HMLER cell line generated through the in vitro transformation of
human mammary cells (Elenbaas et al, 2001; Morel et al, 2008).
Methylated DNA fragments were selected using a recombinant
protein containing the Methyl-CpG-binding domain of MBD2 of
MBD2 (Methyl-Cap-seq), from MDA-MB-231 cell line derived from
EMBO Molecular Medicine Vol 8 | No 8 | 2016 ª 2016 The Authors
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Figure 1. NTN1 and DAPK1 are hypermethylated and downregulated in human breast cancers.
A, B DNA methylation level of NTN1 (A) and DAPK1 (B) 50 regions (Illumina’s HumanMethylation450K Array (HM450) from The Cancer Genome Atlas breast cohort) in
paired breast tissues (normal: green circles, tumor: red circles), n = 92, Wilcoxon matched-pairs signed rank test, P = 0.004 and P = 0.0008.
C, D NTN1 (D) and DAPK1 (G) gene expression in paired breast tissues (normal: green bars, tumor: red bars), RNAseq from TCGA breast cohort, n = 112 and 114,
respectively.
E, F Correlation between NTN1 (E) and DAPK1 (F) gene expression and DNA methylation in the breast cancer cohort (TCGA, n = 807). Pearson correlation, P = 6.7.105,
r = 0.14 for NTN1 (A) and P < 1016, r = 0.32 for DAPK1 (B), respectively.
G, H Tumor/normal DNA methylation ratio of NTN1 (G) and DAPK1 (H) in human breast tumors (data extracted from TCGA cohort, paired samples) according to gene
expression (downregulated FC ≤ 0.5, down, n = 33, or upregulated FC ≥ 1.3, up, n = 16). P = 3 × 102 and P = 3 × 104 two-sided Mann–Whitney test, for NTN1
and DAPK1, respectively.
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Figure 2. DNA methylation and demethylation in mammary cell lines.
A Methyl-Cap-seq read density profiles of the 50 end of DAPK1, UNC5B, and NTN1 in MDA-MB-231 (blue) and HMLER (green) cells. Red boxes represent the CpG islands
(CGis); light gray boxes the regions analyzed by bisulfite PCR sequencing; dark gray boxes represent the regions analyzed by parallel sequencing of amplicons from
bisulfite modified DNA; and black boxes represent the exons and UTR. Chromosome coordinates of each gene are given (black lines).
B, C Gene expression was measured by qRT–PCR after 72 h for MDA-MB-231 (B) and HMLER cells (C) treated daily with DAC (10 lM). PBGD expression level was used as
an internal control. Data are expressed as mean  s.e.m. of at least 3 independent experiments. ****P < 0.0001, two-tailed unpaired Student’s t-test.
D, E Measurement of DNA hypomethylation of the DAPK1 (D) and NTN1 (E) promoters after decitabine treatment of MDA-MB-231 and HMLER cells. Over 1960
sequences were analyzed per group in 2 independent experiments. ****P < 0.0001, two-way ANOVA and post hoc Tukey test.
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human breast cancer, and the HMLER cell line constructed from
in vitro transformation of human mammary cells (Elenbaas et al,
2001; Morel et al, 2008). Data obtained indicated that the 50-end
CpGis of DAPK1 and NTN1 were methylated in the two cancer cell
lines (Fig 2A). Furthermore, the treatment of MDA-MB-231 and
HMLER cells with decitabine (DAC) resulted in a significant upregu-
lation of DAPK1 and NTN1 mRNA (Fig 2B and C) and in the inhibi-
tion of DNA methylation within the DAPK1 and NTN1 promoter
regions (Figs 2D and E, and EV1F and G).
Parallel sequencing of DMRs (Fig 2A, dark gray boxes) validated
their methylation status obtained from Methyl-Cap-seq experiments
and indicated that DAC treatments reduced their level of methyla-
tion by half, in vitro (Fig 2D and E). Of note, DAC treatment of
MDA-MB-231 cells resulted in the upregulation of UNC5B, although
its promoter was not methylated in any of the cell lines tested
(Fig 2B and C), suggesting an indirect regulatory mechanism.
However, this upregulation was not observed for the other netrin-1-
specific receptors, UNC5A, UNC5C, and DCC (Fig EV2A and B).
Altogether, these data strongly suggest that DNA hypermethylation
is involved in the transcriptional silencing of DAPK1 and NTN1 in
human breast cancer cells.
Decitabine resensitizes cancer cells to netrin-1
interference in vitro
We thus hypothesized that the pharmacological targeting of the DNA
methylation machinery may restore functional netrin-1/DR path-
ways and resensitize netrin-1-low cells to netrin-1 interference. We
investigated whether the forced expression of DAPK1 in the DAPK1-
negative HMLER cells re-established pro-apoptotic pathways
(Fig EV2C and D). As expected, an increase in caspase-3 activity was
observed in DAPK1 transfected cells. Furthermore, this pro-apoptotic
effect was partially reversed by adding recombinant netrin-1
(Fig EV2D). We next analyzed cell death by conducting viability
assays and caspase-3 activity assays in HMLER cells transfected with
NTN1 siRNA and treated with DAC. While transfections had a mild
effect on HMLER cells per se, treatment with DAC strongly potenti-
ated the netrin-1 deprivation-induced cell death (Fig EV2F–H).
Keeping in mind the therapeutic perspective of our study, we
assessed the effect of combining DAC with a human anti-netrin-1
antibody, net1-mAb (Grandin et al, 2016). MDA-MB-231 and
HMLER cells were treated with DAC or net1-mAb, or a combination
of both drugs. As anticipated, the cell lines were resistant to
net1-mAb alone, while, as previously observed (Lund et al, 2011)
(Rodriguez-Paredes & Esteller, 2011b), DAC induced cell death in
most of the cells tested, as evidenced by DNA fragmentation
(Figs 3A and B, and EV2I and J) and viability assays (Fig 3C). The
addition of net1-mAb to DAC-treated cells significantly enhanced
apoptosis (Fig 3A–C). Moreover, this effect was blocked by the
concomitant addition of recombinant netrin-1 (Fig 3A–C), indicating
that net1-mAb-induced cell death was specifically linked to netrin-1
neutralization. To confirm that the pro-apoptotic activity observed
upon the combined net1-mAb and DAC treatment was not linked to
an intrinsic property of DAC, MDA-MB-231 and HMLER cell lines
were treated with the 5-azacytidine (Aza), a DNA methylation inhi-
bitor. This treatment resulted in similar gene expression modifi-
cations and cell death effects as DAC, when combined with the
net1-mAb (Appendix Fig S1). The functional consequences of this
combination treatment were also evaluated in additional human
breast cancer cell lines. The highest upregulation of both NTN1 and
DAPK1 was observed when treating cells with 10 lM of DAC
(Fig EV3A–E), we thus used this concentration in the combined
DAC and net1-mAb treatment to investigate the induction of apopto-
sis (Fig EV3F). A similar potentiation of cell death by combining
DAC and net1-mAb was observed in cell lines (AU565, SKBR3, and
MDA-MB-157) exhibiting an upregulation of at least one of 3 genes,
NTN1, UNC5B, or DAPK1 (Fig EV3C–E).
The combination of the netrin-1 neutralizing antibody
with decitabine inhibits tumor growth and metastasis
in animal models
We next investigated whether the inhibition of DNA methylation
could also re-establish the netrin-1/DRs-mediated pro-apoptotic
pathways in vivo. Nude mice were engrafted with MDA-MB-231
cells in the mammary fat pad as an orthotopic site for breast cancer.
When tumors were palpable (100 mm3), DAC was subcutaneously
injected at a therapeutic dose (0.5 mg/kg). Parallel sequencing of
amplicons derived from DAPK1 and NTN1 CGis indicated that these
genes were also hypomethylated (ranging from 5 to 27% depending
of the CpG analyzed) in tumors from DAC-treated mice (Fig 3D).
Furthermore, we observed that DAC treatments were associated
with the re-expression of DAPK1, netrin-1, and UNC5B by the IHC
staining of tumor sections (Fig 3E and F).
To evaluate the effect on tumor growth, MDA-MB-231 orthotopic
xenografts were performed, and mice were treated by
▸Figure 3. Netrin-1 neutralizing antibody net1-mAb triggers apoptosis in hypomethylated MDA-MB-231 and HMLER breast cancer cell lines.A, B Cells were treated with DAC (10 lM, 72 h), and/or net1-mAb (10 lg/ml, 48 h) and/or recombinant netrin-1 (5 lg/ml, 48 h). TUNEL assays from 3 independent
experiments. ***P < 0.0001 one-way ANOVA.
C Cellular mortality was assessed using the toxilight assay. Data represent mean  s.e.m. from 3 independent experiments. ****P < 0.0001, one-way ANOVA.
D–H MDA-MB-231 cells were implanted into the mammary gland fat pad of immuno-compromised mice. When tumors reached 100 mm3, mice were injected
subcutaneously with decitabine (0.4 mg/kg) or PBS and/or intraperitoneally with net1-mAb (10 mg/kg). (D) Loss of DNA methylation of the NTN1 and DAPK1
promoters in decitabine treated tumors, compared with PBS treated tumors, after one week of treatment. > 1,700 sequences were analyzed per group in 2
independent experiments. ****P < 0.0001, two-way ANOVA and post hoc Tukey-test. (E, F) After one week of treatment, tumors from xenografted mice were fixed
in formalin, embedded in paraffin, and sliced into 4 lm sections. (E) Levels of DAPK1, UNC5B, and netrin-1 were measured in 4 independent tumors per treatment
group by immunohistochemistry staining, and expressed as a percentage of total tumor surface normalized against the control PBS-group. Data represented as
means  s.e.m. ****P < 0.0001, two-way ANOVA and post hoc Tukey-test. (F) Representative tumor sections corresponding to MDA-MB-231 xenografts, scale
bars = 50 lm. (G) Tumor volumes were measured twice a week. The statistical significance of the differences obtained between the control PBS-group and treated
(DAC + net1-mAb) group was determined by two-way ANOVA and post hoc Tukey-test. ***P < 0.0001. Error bars = s.e.m. n = 9 mice per group. (H) Tumor weights
were measured 3 days after the end of the experiment. The statistical significance of the differences obtained between the groups was determined by one-way
ANOVA, ***P < 0.0001. Error bars = s.e.m. n = 9 mice per group.
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intraperitoneal injections of net1-mAb, or subcutaneous injections
of DAC, or a combination of both treatments for a period of 21 days
(Fig 3G and H). While no significant difference was observed
between the control groups and mice treated either with net1-mAb
or DAC alone, the combination of both drugs strongly inhibited
tumor growth (Fig 3G) and led to a reduction in tumor weight
(Fig 3H). Furthermore, similar results were obtained using the
NET1-mAb antibody, which is scheduled for human trials in 2016
(Grandin et al, 2016) (Appendix Fig S2A). Interestingly,
the inhibitory effect of the combined treatment on tumor growth
was associated with a marked increase in tumor cell death
(Appendix Fig S2B and C).
To gain further insights into the mechanisms underlying the
tumor suppressive activity of netrin-1 neutralization following DAC
treatment, cancer cell proliferation and tumor angiogenesis were
analyzed in treated tumors. A small reduction in the proliferative
rate (Ki67 staining) was determined in MDA-MB-231 xenografts
from mice treated with DAC; however, the differences between
treated samples and controls were not statistically significant
(Appendix Fig S3A and B). Staining of sections from MDA-MB-231
xenografts with an antibody directed against CD31 (also known as
platelet endothelial cell adhesion molecule) revealed that the anti-
netrin-1 antibody treatment led to a reduction in angiogenesis. This
finding strengthens a previous report, which suggested the implica-
tion of netrin-1 during angiogenesis (Bongo & Peng, 2014).
However, no statistically significant differences were observed
between mice treated with the anti-netrin-1 antibody alone, where
no inhibition in tumor growth was detected, and the mice treated
with a combination of DAC and net1-mAb, where tumor growth
was profoundly affected (Appendix Fig S3A). Hence, the inhibitory
effect of the combination of DAC and net1-mAb on tumor growth is
likely related to their pro-apoptotic effects, rather than to a change
in proliferation or in angiogenesis.
Finally, the effect of this combination treatment on metastasis
formation was evaluated in a model previously used for monitoring
tumor dissemination (Walker et al, 2004; Delloye-Bourgeois et al,
2009b). MDA-MB-231 cells previously treated with control IgG1,
DAC, and net1-mAb alone or in combination, were seeded onto the
chorioallantoic membrane (CAM) of 10 days old chicken embryos.
Data obtained indicated that CAMs grafted with cells previously
treated with DAC and the net1-mAb exhibited a reduction in the
formation of lung metastasis (Appendix Fig S4).
To move toward a model closer to the human pathology, we
analyzed the effect of combining DAC and the netrin-1 antibody in
mice model bearing a patient-derived tumor (PDX model). Consis-
tently with the data obtained from mice engrafted with cell lines,
DAC treatments induced the hypomethylation of DAPK1 and NTN1
in our PDX (Fig 4A) and increased the levels of DAPK1, UNC5B,
and netrin-1 (Fig 4B and C). Furthermore, IHC staining on tumor
sections indicated that the combination treatment increased the
apoptotic rate (Fig 4D and E), while it was not correlated with
tumor cell proliferation or angiogenesis (Appendix Fig S3C and D).
Similarly to the data obtained in MDA-MB-231 engrafted cells, the
combined treatment reduced the growth of the PDX tumor when
compared to the effects of monotherapies (Fig 4F).
Tumor growth inhibition induced by combining decitabine with
netrin-1 interference is directly mediated by UNC5B and DAPK1
The potential reversibility of epigenetic DNA modifications raised
the possibility that inhibition of DNA methylation might induce the
re-expression of these genes, and thus, resensitize cells to several
pathways resulting in apoptosis. Therefore, we studied gene re-
expression following DAC treatment in MDA-MB-231 and HMLER
cell lines, by RNAseq. Indeed, the 626 upregulated genes upon DAC
treatments (FC untreated/treated cells > 2) both in MDA-MB-231
and HMLER cells were investigated for their Gene Ontology term
and their KEGG pathway contributions using the WEB-based GEne
SeT AnaLysis Toolkit (Wang et al, 2013). Enriched Gene Ontology
terms were of various nature and included response to molecules of
bacterial origin, response to lipopolysaccharide, biological regula-
tion, cell proliferation, and cytokine activity. Enriched KEGG path-
ways included KEGG osteoclast differentiation, KEGG MAPK
signaling pathway, KEGG rheumatoid arthritis, KEGG cytokine–
cytokine receptor interaction, pathways in cancer, and NOD-like
receptor signaling pathway (Appendix Fig S5). Genes upregulated
upon DAC treatment were associated with many biological func-
tions; however, the profiles of transcriptomic changes suggested
that no other pro-apoptotic pathway participated in the synergistic
effect of net1-mAb and DAC on cell death observed herein.
▸Figure 4. DAC treatment triggers upregulation of genes in the netrin-1/dependence receptor signaling pathway, and, when combined with net1-mAb,induces apoptosis and tumor growth inhibition in a mouse model bearing a patient-derived breast tumor.
A Loss of DNA methylation of the NTN1 and DAPK1 promoters in decitabine-treated PDX tumors, compared with the control PBS group. The percentage of mean DNA
methylation of the 11 DAPK1-CpGs was 94% (550 amplicons analyzed), while that of the 7 NTN1-CpGs was 64% (213 amplicons analyzed). Two-way ANOVA and post
hoc Tukey test.
B Expression of DAPK1, UNC5B, and NTN1 was measured by qRT–PCR in PDX tumors after 7 days of in vivo DAC treatment (0.4 mg/kg). The level of PBGD expression was
used as an internal control. Data are expressed as mean  s.e.m. for at least 3 grafts per group. ****P < 0.0001, two-way ANOVA and post hoc Tukey test.
C Levels of DAPK1, UNC5B, and netrin-1 were measured in at least 3 independent paraffin embedded xenografts per treatment group by immunohistochemistry. Data
are expressed as the percentage of the total tumor surface normalized against the median tumor surface of the PBS group. ****P < 0.0001, one-way ANOVA. Error
bars = s.e.m.
D Cleaved caspase-3 and DNA fragmentation (TUNEL) median number of cells per mm2 were measured in treated xenografts. Data represent mean  s.e.m. from at
least 3 tumors per group. ****P < 0.0001, one-way ANOVA.
E Representative sections of the xenograft PDX analyzed in (D). Scale bars = 50 lm. Arrows indicate positive staining.
F The combination of net1-mAb and DAC reduces human breast tumor growth in immuno-compromised mice. After anesthesia, mice were engrafted in the
interscapular area with a  60 mm3 patient-derived tumor. When the tumors reached 120–150 mm3, mice were injected subcutaneously with decitabine
(0.4 mg/kg) or PBS and/or intraperitoneally with net1-mAb (10 mg/kg) or with a human IgG1 control isotype antibody (Ctrl IgG1, 10 mg/kg) from day 1 to day 21.
Tumor volumes were measured twice a week; n = 7 mice per group. The statistical significance of the differences obtained between the DAC + Ctrl IgG1 group and
the DAC + net1-mAb group was determined by two-way ANOVA2 and post hoc Tukey test, ****P < 0.0001. Error bars = s.e.m.
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It has been reported (Qi et al, 2015) that the addition of netrin-
1 to the culture medium of human liver cancer, glioblastoma, and
embryonic kidney cell lines induces the expression of the Yes-
associated protein (YAP), of TAZ, a transcriptional coactivator
with a PDZ-binding motif (WWTR1), and of the connective tissue
growth factor (CTGF), the transcription of which is initiated by
YAP/TAZ. The induction of YAP/TAZ following the addition
netrin-1 was correlated with an increase in cell proliferation and
following the addition of netrin-1 neutralization by specific anti-
bodies, with a decrease in the proliferation and migration of the
cell lines analyzed (Qi et al, 2015). Therefore, we verified
whether, in DAC-treated cells, netrin-1 neutralization leads to the
downregulation of the YAP/TAZ signaling pathway, which, in
turn, could participate in the anti-tumoral effects associated with
the combined treatment. The effect of the net1-mAb on the expres-
sion of YAP, TAZ, and CTGF, in MDA-MB-231 and HMLER cells
treated with DAC, was thus investigated. In MDA-MB-231 cells,
DAC treatment increased the level of TAZ and CTGF expression,
while net1-mAb treatment only induced a slight increase in TAZ
expression. In contrast, in HMLER cells, the addition of net1-mAb
only induced the expression of CTGF in DAC-treated cells, while
the expression of YAP and TAZ was not significantly modified
(Appendix Fig S6A and B). Collectively, these observations did not
seem to be in favor of major role of the YAP/TAZ-mediated
signals in the response of cancer cells to the combined DAC/
+net1-mAB treatment. In a similar context, p53 alterations were
reported to cooperate with YAP signaling pathways during cancer
cell proliferation (Di Agostino et al, 2016), raising the question of
the implication of TP53 in the apoptotic effect observed. In the
panel of cells analyzed, T47D cells exhibited no alteration in p53
and did not respond to the combined treatment (Fig EV3F), while
other cell lines, mutated (MDA-MB-231), blocked (HMLER), or
wild type (H460) responded to the combined DAC/+net1-mAb
treatment (Grandin et al, 2016). Taken together, these data
suggested that TP53 does not play a determinant role in the tumor
growth inhibitory effect conferred by the combination treatment.
Similarly to the data reported by Roulois et al (2015) in colorec-
tal cancer cells, DAC treatment of MDA-MB-231 and HMLER cells
induced the interferon regulatory factor 7 (IRF7), a key player in the
type I interferon (IFN)-dependent immune responses (Appendix Fig
S6C and D). We thus investigated the effect of this transcriptional
regulator on the expression of DAPK1, NTN1, or UNC5B upon DAC
treatment in MDA-MB-231 and HMLER cells. The transient transfec-
tion of these two cell lines with a siRNA targeting IRF7 strongly
reduced IRF7 expression and prevented its upregulation upon DAC
treatment (Appendix Fig S6C and D). However, IRF7 mRNA deple-
tion failed to abrogate DAC induction of DAPK1, NTN1, and UNC5B
upregulation, suggesting that IRF7 and more generally the interferon
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Figure 5. Sensitivity ofMDA-MB-231 cell lines stably transfectedwith shRNA targeting DAPK1,UNC5B, andNTN1 to treatments combining DAC and net1-mAb.
A–D Stably transfected MDA-MB-231 cells bearing a control (A), DAPK1 (B), UNC5B (C), or NTN1 shRNA (D) were injected into the mammary fat pad of immuno-
compromised mice. When tumors reached 100–120 mm3, mice were injected subcutaneously with DAC (0.4 mg/kg) or PBS and/or intraperitoneally with net1-mAb
(10 mg/kg). Tumor volumes were measured twice a week, n = 8 mice per group. The statistical significance of the differences obtained between DAC group and
DAC + net1-mAb group for shControl, DAC group and DAC + net1-mAb group for shDAPK1 and shUNC5B, and PBS group and DAC group for shNTN1, respectively,
was determined by two-way ANOVA and post hoc Tukey test. ****P < 0.0001, ns = not significant. Error bars = s.e.m.
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(IFN)-like response is not implicated in regulating the expression of
these genes following DAC treatment.
Our final working hypothesis was, therefore, that the tumor
growth inhibitory effects conferred by the combination treatment
were mediated through the pro-apoptotic DR pathway. To validate
this hypothesis, we generated MDA-MB-231 cells stably expressing
shRNAs targeting DAPK1, NTN1, or UNC5B transcripts. qRT–PCR
analyses indicated that the DAC-induced expression of DAPK1,
NTN1, and UNC5B was efficiently counteracted by gene silencing in
the corresponding MDA-MB-231-shDAPK1, MDA-MB-231-shNTN1,
and MDA-MB-231-shUNC5B cells (Fig EV4A). We then investigated
the responses of the MDA-MB-231-shRNA cells, when engrafted in
mammary fat pad and treated or not with the combination treatment
(DAC and the net1-mAb). After validating the levels of DAPK1,
UNC5B, and netrin-1 by IHC (Fig EV4B–D), anti-active caspase-3
IHC staining was performed on tumor sections and revealed that the
silencing of DAPK1 or UNC5B fully prevents the activation of
caspase-3 mediated by the combination treatment, while DAC
monotherapy resulted in a marked increase in caspase-3 activity
when NTN1 was silenced. Furthermore, the silencing of DAPK1 or
UNC5B mRNA prevented the inhibition of tumor growth induced by
the combination treatment, further confirming our working hypoth-
esis (Fig 5A–C). Moreover, NTN1 silencing was sufficient to induce
tumor growth inhibition following DAC monotherapy (Fig 5D).
Taken together, these data demonstrate that DAPK1 and UNC5B are
the key players involved in the response to the combined DAC and
the anti-netrin-1 antibody treatment.
Discussion
The results presented herein provide a proof of concept that inhi-
bition of DNA methylation can sensitize solid tumors to antibod-
ies mediating tumor cell apoptosis. We previously proposed that
in netrin-1-low tumors, inhibition of the netrin-1 dependence
receptor (DR) pathway may occur either through the downregula-
tion of the receptors or of key signaling pathway partners in
colorectal cancer and neuroblastoma (Bernet et al, 2007; Zhu
et al, 2013). Interestingly, in the panel of breast cancers analyzed
in the current study, low levels of NTN1 expression are associ-
ated with the hypermethylation of the CpG island located in the
50-end of this gene. Furthermore, this correlation between hyper-
methylation and gene silencing was also found for DAPK1, an
essential partner in the apoptotic netrin-1/DR pathway. These
features were confirmed in breast cancer cell lines, since NTN1
was downregulated and methylated in HMLER and MDA-MB-231
cells, and DAPK1 was methylated and downregulated in HMLER
cells.
In addition we showed, both in vitro and in xenograft models,
that combining inhibition of DNA methylation with an anti-netrin-1
antibody resulted in the re-expression of netrin-1 and DAPK1 and
led to tumor cell death and tumor growth inhibition. The correlation
between NTN1 and DAPK1 silencing and DNA hypermethylation
does not exclude that their upregulation in DAC-treated cells might
be dependent on additional factors. For example, UNC5B, while
unmethylated, was upregulated in DAC-treated MDA-MB-231 cells,
and it was previously shown that in breast cancer cells, the down-
regulation of some methylated genes is dependent on the deposition
of the methyl-CpG binding domain protein 2 (MBD2) within their
promoter sequence (Devailly et al, 2015).
It is intriguing that, in the PDX model, the administration of DAC
as a monotherapy only resulted in a slight tumor growth inhibitory
effect. It is unlikely that the resistance to DAC treatment, used as a
monotherapeutic agent, may have resulted from an over- or under-
dosage, since several reports have shown that similar DAC doses
are efficient in reducing tumor formation in some mouse models,
including ApcMin-induced intestinal neoplasia (Tsai et al, 2012),
HRAS-G12V-transformed human epithelial kidney, leukemic cells,
breast cancer cell lines, and engrafted patient-derived tumors (Mian
et al, 2011; Kilinc et al, 2012). Furthermore, DNA hypomethylation
was observed following DAC treatment in MDA-MB-231 xenograft
tumors and PDX, indicating that DNA methylation was efficiently
inhibited by DAC, in vivo. Alternatively, these data would suggest
that tumor-growing conditions can overcome, at least partially, the
anti-tumor effect of DAC. Experimental approaches (Rodriguez-
Paredes & Esteller, 2011b; Yang et al, 2012; Azad et al, 2013) and
clinical trials (ClinicalTrials.gov http://www.clinicaltrials.gov)
using combinations of DAC with other epigenetic modifiers and/or
cytotoxic agents provide interesting strategies for tumor growth
reduction. However, these approaches have overlooked an impor-
tant aspect of DAC, which is the re-expression of potentially masked
targets and pathways. The data reported here provide not only
evidence for the importance of ligand/DRs pairs in the regulation of
tumor development but also advocate a new strategy based on the
specific targeting of genes re-expressed following a DNA
hypomethylating treatment. Finally, inhibitors of DNA methylation
could “prime” tumors to netrin-1 addiction, and the subsequent
treatment with a combination of inhibitors of DNA methylation and
an anti-netrin-1 antibody could result in a powerful therapeutic
strategy.
Materials and Methods
Tumor samples
Human breast cancer samples were provided by the tumor bank of
the Centre Le´on Be´rard (Lyon, France). Fresh tissue samples were
obtained during breast surgery, prior to any systemic therapy, snap-
frozen in liquid nitrogen, and stored for scientific research in a
biological resources repository, according to the French National
Ethical Guidelines. Tissue microarrays of paraffin embedded breast
tumor sections were obtained from Super Bio Chips (Cliniscience,
Nanterre, France).
Cell lines and treatments
The HMLER, MDA-MB-157, MDA-MB-231, and MDA-MB-231-Luc
breast cancer cell lines (Cell Biolabs, San Diego, CA, USA) were
maintained in Dulbecco’s Minimum Essential Medium F12 Glutamax
(DMEM-F12 Glutamax) (Life Technologies). In addition, human
EGF 10 ng/ml (Promocell, Heidelberg, Germany), hydrocortisone
0.5 lg/ml, puromycin 0.5 lg/ml (InVitrogen), and insulin 10 lg/ml
(InVitrogen) were added to the medium of HMLER cells. AU565 and
T47D cell lines were maintained in RPMI medium (Life Technolo-
gies), supplemented with insulin 0.2 U/ml (InVitrogen) for T47D
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cells. SKBR3 cells were maintained in McCoy’s medium (Life Tech-
nologies). All of these cell lines were supplemented with 10% FBS
(Lonza, Basel, Switzerland) and 1% penicillin/streptomycin
(InVitrogen, Carlsbad, CA, USA). Twenty-four hours after plating,
cells were grown for 3 days in fresh medium containing various
concentrations of decitabine (5-aza-20-deoxycytidine, DAC) (Sigma-
Aldrich) or 2 lM 5-azacytidine (Sigma-Aldrich), renewed every
day. The cells were then cultured, under serum deprived condi-
tions for 48 h, in the presence of the net1-mAb anti-netrin-1 anti-
body (10 lg/ml) (Netris Pharma, Lyon, France), as well as in the
presence or not of the recombinant Flag-tagged netrin-1 (5 lg/ml)
(Adipogen).
Enforced gene expression and siRNA experiment
The pcDNA3.1 vector coding for DAPK1 (Llambi et al, 2005) was
used to enforce the expression of DAPK1 in HMLER cells. Empty
plasmids or plasmids containing a HA-tagged DAPK construct were
transfected into HMLER cells using Lipofectamine 2000 (Invitrogen).
NTN1 siRNA has been previously described (Delloye-Bourgeois
et al, 2009a) and was transfected using Lipofectamine 2000 into
HMLER cells, which were previously treated or not with decitabine
for 72 h. IRF7 siRNA was transfected using Lipofectamine 2000, and
transfected cells were treated for 72 h with DAC. Scramble siRNA
(Sigma) was used as a control.
Stable shRNA transfection of cell lines
Control, DAPK1, UNC5B, and NTN1 shRNA plasmids (Sigma
Mission shRNA) were transfected into subconfluent cells using Lipo-
fectamine 2000, according to the manufacturer’s protocol. After
transfection, puromycin (2 lg/ml) was added to the fresh medium
as a selection factor. The selection of transfected cells occurred over
a 5-day time-course. Cells were then trypsinized and diluted to
obtain 0–2 clones per well in 96-well plates. Cell selection using
puromycin (2 lg/ml) was conducted throughout the shRNA trans-
fection, selection, and all of the subsequent experiments, in order to
conserve gene downregulation. Following their amplifications, cells
were treated or not with DAC, and tested for their level of DAPK1/
UNC5B/NTN1 expression before and after DAC treatment. Clones
that exhibited a “normal” proliferation rate and a low level of
expression of the gene of interest were selected.
Caspase-3 activity and viability assays
Caspase-3 activity was measured as previously described
(Llambi et al, 2005), (Delloye-Bourgeois et al, 2009a) using the
Ac-DEVD-AFC substrate assay (Gentaur Biovision, Brussel,
Belgium). Alternatively, the percentage of cell death was measured
by acridine orange and DAPI staining, using the NucleoCounter NC-
3000 system (ChemoMetec A/S, Allerød, Denmark).
Fluorescent caspase-3 activity
The apoptotic index was measured using the CellPlayer 96-Well
Kinetic Caspase 3/7 Apoptosis Kit, according to the manufacturer’s
protocol (Essen bioscience, Hertfordshire, UK). Three thousands
cells were plated in 96-well plates, treated with DAC (10 lM final) or
vehicle (PBS) for 48 h. The cells were then incubated in serum free
medium enriched with a kinetic apoptosis reagent (1/5,000e), with
net1-mAb (10 lg/ml) and/or with recombinant netrin-1 (5 lg/ml),
and with DAC or PBS. Cells were placed in an IncuCyte FLR or
ZOOM with a 10 × objective in a standard cell culture incubator at
37°C and 5% CO2 for 48 h. As a marker of proliferation, and to
correct for differential proliferation of cells, the total number of
DNA-containing objects was counted at the end of the experimental
time-course, using Vybrant Green. This number was used to calcu-
late the “apoptotic index”, defined as the ratio of the number of
caspase-3/7 positive objects to the total number of DNA-containing
objects, as recommended by the manufacturer’s protocol.
TUNEL assays
For the detection of DNA fragmentation, cells were cultured on
coverslips, and, after treatments, fixed in 4% paraformaldehyde for
20 min. TUNEL assays (terminal deoxynucleodityl-transferase-
mediated dUTP-biotin nick end labeling) were then performed using
300 U/ml TUNEL enzyme and 6 lM biotinylated dUTP, according to
the manufacturer’s guidelines (Roche Diagnostics, Meylan, France).
Mouse model of xenografts
Five-week-old female athymic Swissnu/nu mice were obtained from
Charles River (Ecully, France) and were housed in a specific
pathogen-free animal facility. MDA-MB-231 or MDA-MB-231-Luc
shRNA cells (2 × 106) were resuspended in 200 ll PBS and
implanted into the mammary gland fat pad. When tumors reached
an approximate volume of 100 mm3, 10 mg/kg of net1-mAb (Netris
Pharma, France) or an equal volume of PBS (Life Technologies) was
injected intraperitoneally, twice a week for 3 weeks. DAC was then
injected subcutaneously into the left flank 3 times a week for
3 weeks (dosage: 0.5 mg/kg; vehicle: PBS) or replaced by PBS in
the control groups. Tumor volumes were assessed twice a week
with a caliper and calculated with the formula V = ½
(length × width2). Furthermore, a patient-derived xenograft, PDX-
HBC-146, was generated and housed in the tumor model laboratory
(LMT) of the Centre Le´on Be´rard. Briefly, following isoflurane anes-
thesia, mice were engrafted in the interscapular area with
a  60 mm3 patient-derived tumor. When tumors reached 120–
150 mm3, mice were injected subcutaneously with DAC (0.5 mg/kg)
or PBS 3 times a week for 3 weeks and/or intraperitoneally with
net1-mAb (10 mg/kg) or with a human IgG1 control isotype anti-
body (Ctrl IgG1, 10 mg/kg, Evitria, Switzerland) twice a week for
3 weeks. Concomitantly, in order to evaluate the effects of the
treatments on DNA methylation, cell death, cell proliferation,
tumor angiogenesis, and protein expression, some xenografted
mice were treated for only one week (as described above) before
tumor extraction for further analysis. All experiments were
performed in accordance with the relevant guidelines and regula-
tions required by the Animal Ethics Committee (accreditation of
laboratory animal care by CECCAP, ENS Lyon-PBES).
Chicken model for tumor cell dissemination
As previously described (Delloye-Bourgeois et al, 2009b), MDA-MB-
231 cells were initially treated for 3 days with DAC 10 lM or PBS
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(vehicle) and then for 2 days with Control Iso-mAb or net1-mAb.
After trypsinization, 2 × 106 cells were suspended in 100 ll of PBS/
Matrigel (1:1) and seeded on the chorioallantoic membrane (CAM)
of 10-day-old chicks. On day 17, lungs were harvested from the
tumor-bearing embryos and genomic DNA was extracted with a
NucleoSpin Tissue kit (Macherey-Nagel). Metastasis was quantified
by PCR-based detection of the human Alu sequence, using primers
for avian repeated element-specific sequences as controls (see
Appendix Table S1). For both couples of primers, metastasis was
assessed by polymerase activation at 95°C for 2 min followed by 40
cycles at 95°C for 30 s, 63°C for 30 s, and 72°C for 30 s. Genomic
DNA extracted from chicken breast and lungs of healthy chick
embryos was used to determine the threshold between neuroblas-
toma (NB) cell-invaded and non-invaded lungs. All experiments
were performed in accordance with the relevant guidelines and
regulations required by the Animal Ethics Committee (accreditation
of laboratory animal care by CECCAP, ENS Lyon-PBES).
Immunohistochemistry analysis of xenografted cell lines and
patient biopsies
Immunohistochemistry staining was performed on an automated
immunostainer (Ventana Discovery XT, Roche, Meylan, France)
using the DABmap Kit according to the manufacturer’s instructions.
Tissue samples were fixed in 10% buffered formalin and embedded
in paraffin. Following antigen unmasking (citrate buffer pH 7.3,
98°C for 35 min), immunostainings were performed with a poly-
clonal rat anti-mouse netrin-1 antibody (R&D), a rabbit polyclonal
anti-DAPK1 (Acris), or an UNC5B antibody (Sigma), using the
Novolink kit (Leica) for revelation. Apoptotic cell staining was
performed using a rabbit cleaved caspase-3-specific antibody (Cell
Signaling) and the In Situ Cell Death Detection kit POD (Roche).
Angiogenesis was measured using a rabbit polyclonal CD31 (Platelet
Endothelial Cell Adhesion Molecule-1) antibody (ANASPEC), and
the rate of cell proliferation was determined using a mouse mono-
clonal MIB-1-specific antibody (DAKO). Image analysis was
performed using a light microscope (Eclipse E400, Nikon France,
Champigny, France) equipped with a tri-CDD video camera (Sony,
Japan). Quantitative values were determined by morphometric anal-
ysis (Histolab, Microvision Instruments, Evry, France) of at least 40
fields per staining at a ×200 magnification for the xenograft tumor
sections, and one field per staining of the total tissue section at ×40
magnification for the tissue microarray. The total surface occupied
by the tumor was automatically measured, and the positively
stained at each surface was expressed as a percentage of the total
surface for each field analyzed.
RNA isolation
Total RNA was extracted from biopsies and xenografts using the
TRIzol-Reagent (Ambion, Life Technologies) and from cell lines
using the Nucleospin RNAII kit (Macherey-Nagel, Hoerdt,
Germany), according to the manufacturer’s instructions. For RNA-
seq experiments, RNA purity, integrity, and quantification were
assessed using agarose gel electrophoresis and a NanoDrop 1000
(Thermo Scientific, Wilmington, DE, USA). Pools of three to five
independent extractions were sent for high-throughput sequencing
to the Beijing Genomics Institute (BGI, Hong-Kong, China).
Reverse transcription and quantitative real-time RT–PCR
One microgram of RNA was reverse-transcribed, using the iScript
cDNA Synthesis Kit (Bio-Rad, Ivry, France). Quantitative RT–PCR
was performed using a Mini opticon (Bio-Rad) and the SYBR super-
mix qPCR kit (Bio-Rad). Polymerase was activated at 95°C for
3 min, followed by 45 cycles of amplification and 30 s of cooling.
Moreover, gene expression profiles of human samples and cell lines
were validated using 3 other standard housekeeping genes, namely
PBGD, GAPDH, and MBD2, to confirm the results. Primer sequences
for the genes targeted are shown in Appendix Table S1.
DNA extraction
Biopsy samples and xenografted cell lines were cryogrinded in
liquid nitrogen. DNA was then extracted and purified using the
Nucleospin tissue DNA extraction kit (Macherey-Nagel), according
to the manufacturer’s protocol. DNA from cell lines was directly
extracted using the standard protocol (Auriol et al, 2005).
Bisulfite treatment of genomic DNA
Two hundred nanograms of genomic DNA was added to 1.8 lg of
standard plasmid DNA (pGL3 Basic) and converted using the Epitect
Bisulfite kit (Qiagen), according to the manufacturer’s protocol.
Amplification of bisulfite converted DNA and pyrosequencing
Sets of biotinylated NTN1, DAPK1, and primers were designed
within the promoter region (Fig 1D). As a control, non-modified
and modified GAPDH sets of primers were used to assess the effi-
ciency of the bisulfite DNA conversion. Modified DNA was ampli-
fied in a total volume of 50 ll using the Hotstartaq (Qiagen) kit, in
the presence of 1 mM MgCl2 for the DAPK1 and NTN1 primers.
Thermal profiles were as follows: 95°C for 10 min followed by
50 cycles of 95°C for 30 s, 50°C (NTN1) or 52°C (DAPK1) for 30 s
and 1 min 30 s (NTN1 and DAPK1) of extension followed by a
10-min final elongation. The primer sequences are shown in
Appendix Table S1. The quality and quantity of the PCR product
were confirmed on a 2% agarose gel.
PCR products were then pyrosequenced using the Pyromark kit
(Qiagen). Reverse single-stranded biotinylated templates were
isolated using the PyroMark Vacuum Prep WorkStation (Qiagen).
Forty microliters of PCR product was added to 38 ll of binding
buffer (Qiagen) and 2 ll streptavidin sepharose high-performance
beads (GE Healthcare). The mixtures were shaken for 10 min at
200 g (revolution per minute). After agitation, beads covered with
biotinylated DNA were collected and retained on the filter probes by
permanent vacuum. The filter probes were successively immerged
in different baths: in ethanol 70% for 5 s, in PyroMark denaturation
solution for 5 s, and in PyroMark wash buffer 1× for 15 s (Qiagen).
The vacuum was then turned off, and the beads fixing DNA strands
were released into a 96-well plate containing 25 ll of annealing
buffer with 0.3 lM of sequencing primer in each well. The sequenc-
ing plate was kept at 80°C for 2 min and at room temperature for
5 min. Pyrosequencing reactions were performed in a PyroMark
Q96 system using PyroGold reagents (Qiagen). Results were
analyzed using the PyroMark Software.
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DNA methylation analysis
Bisulfite sequencing, used to determine the CpG methylation
patterns of DAPK1 and NTN1 50UTR regions (Appendix Table S1),
was performed as described (Beygo et al, 2013). Briefly, after a first
amplification using sequence-specific primers, PCR fragments were
tagged in a second amplification step and sequenced using the
Roche/454 GS junior system according to the manufacturer’s proto-
col (Roche emPCR Amplification Method Manual—Lib-A and Roche
Sequencing Method Manual). Data were analyzed using Amplikyzer
(https://pypi.python.org/pypi/amplikyzer/0.97).
Methyl-Capture-sequencing (Methyl-Cap-seq)
Genomic DNAs (1 lg) were sheared to an average length of
300–600 bp. Methylated DNA fragments were isolated using beads
containing the Methyl-CpG-binding domain of MBD2, according to
manufacturer’s recommendations (MethylMiner, InVitrogen). After
sequencing, using the Illumina 2000 high-throughput sequencing
technology by BGI service (Beijing, China), 30–40 million 50-bp
reads were obtained for each input and bound fraction and analyzed
using R and bioconductor packages.
RNA-seq analysis
Reads were aligned on the UCSC Homo sapiens hg19 genome using
TopHat2. Differential expression analyses were performed as
described (Kim et al, 2013), using the Galaxy server (https://usega
laxy.org/). Only genes with at least 1 read per million (RPM) were
kept for subsequent analyses. Enriched Gene Ontology terms and
KEGG pathways were identified using Gene Set Enrichment Analysis
(Subramanian et al, 2005) with genes preranked according to their
fold change induced by DAC treatment.
Data deposition
The MeDP and the RNAseq data from this publication have been
submitted to the GEO database the accession number GSE80177.
Expanded View for this article is available online.
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